BiogenBIIB

NASDAQ · USA · Segment 3 of 8 in the Medicine, pharma & life science value chain: Biotech & innovation

Neurological disease is the whole focus, from multiple sclerosis to Alzheimer's, where Leqembi is partnered with Eisai.

Biotech & innovation: Innovation-driven biotech companies focused on novel treatment modalities.

Key metrics

Market cap

$31B

Price

$218.12

Today

+0.6%

Return YTD

+23.2%

Return 1Y

+55.8%

P/E

37.2

P/S

3.1

P/B

1.6

Data as of 2026-08-25 · updates daily after U.S. close

Theme exposure

BiotechNeurologyAlzheimer's

In the value chain

Products & services

Alzheimer's (Leqembi)
Multiple sclerosis
Rare diseases

Competitors

Eli Lilly (Alzheimer's)
Roche
Novartis

Risks

Leqembi uptake
Declining MS revenue

Supply chain

Supplies →

McKessonMCK

← Suppliers

IQVIA HoldingsIQV

Full supply chain for BIIB →

Same segment: Biotech & innovation

AmgenAMGN Gilead SciencesGILD Vertex PharmaceuticalsVRTX RegeneronREGN Alnylam PharmaceuticalsALNY ModernaMRNA IncyteINCY United TherapeuticsUTHR

Compare BIIB

BIIB vs AMGN BIIB vs GILD BIIB vs VRTX BIIB vs REGN BIIB vs ALNY BIIB vs MRNA

See where Biogen sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →